Payment overview · 2025
General Payments
$820.04
44 reported records · 15 companies
Healthcare provider profile · identity verified
Brian Keith Keller, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUMMERVILLE, SC · NPI 1215994959
Verified facts
What the public records show
CMS Open Payments records show Brian Keith Keller, MD received $820.04 in general payments during 2025 across 44 reported records.
Amgen Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $168.26 | 20.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.62 | 16.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $102.48 | 12.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.53 | 7.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.23 | 6.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.94 | 6.3% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $47.30 | 5.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.71 | 5.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.79 | 3.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.35 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.53 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.48 | 2.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.59 | 2.5% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $16.97 | 2.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.26 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $820.04 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $147.72 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $147.72 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $116.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $102.48 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.23 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.94 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.67 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 248 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 69 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 19 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1483 | 422 |
| Amlodipine Besylate | Amlodipine Besylate | 810 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 675 | 178 |
| Metformin Hcl Er | Metformin Hcl | 605 | 179 |
| Omeprazole | Omeprazole | 593 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 523 | 163 |
| Ezetimibe | Ezetimibe | 473 | 142 |
| Lisinopril | Lisinopril | 426 | 128 |
| Losartan Potassium | Losartan Potassium | 418 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 405 | 125 |
| Gabapentin | Gabapentin | 395 | 121 |
| Pravastatin Sodium | Pravastatin Sodium | 369 | 104 |
| Valsartan | Valsartan | 324 | 87 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 92 |
| Furosemide | Furosemide | 284 | 95 |
| Carvedilol | Carvedilol | 282 | 85 |
| Simvastatin | Simvastatin | 275 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 67 |
| Jardiance | Empagliflozin | 248 | 61 |
| Potassium Chloride | Potassium Chloride | 235 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 232 | 119 |
| Sertraline Hcl | Sertraline Hcl | 228 | 68 |
| Metformin Hcl | Metformin Hcl | 223 | 70 |
| Allopurinol | Allopurinol | 222 | 68 |
| Prednisone | Prednisone | 214 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 199 | 90 |
| Eliquis | Apixaban | 198 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 40 |
| Montelukast Sodium | Montelukast Sodium | 156 | 45 |
| Glimepiride | Glimepiride | 154 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 144 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 45 |
| Ozempic | Semaglutide | 134 | 30 |
| Trazodone Hcl | Trazodone Hcl | 129 | 43 |
| Glipizide Er | Glipizide | 121 | 32 |
| Spironolactone | Spironolactone | 119 | 38 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 117 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 33 |
| Meloxicam | Meloxicam | 111 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 38 |
| Tramadol Hcl | Tramadol Hcl | 110 | 43 |
| Alendronate Sodium | Alendronate Sodium | 108 | 34 |
| Farxiga | Dapagliflozin Propanediol | 106 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 33 |
| Famotidine | Famotidine | 101 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 101 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 100 | 25 |
| Atenolol | Atenolol | 99 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 96 | 23 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 95 | 27 |
| Mounjaro | Tirzepatide | 93 | 15 |
| Fenofibrate | Fenofibrate | 91 | 27 |
| Bupropion Xl | Bupropion Hcl | 90 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 23 |
| Donepezil Hcl | Donepezil Hcl | 84 | 27 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 84 | 76 |
| Pregabalin | Pregabalin | 84 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 21 |
| Trulicity | Dulaglutide | 78 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 42 |
| Buspirone Hcl | Buspirone Hcl | 73 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 12 |
| Synthroid | Levothyroxine Sodium | 69 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 23 |
| Telmisartan | Telmisartan | 66 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Finasteride | Finasteride | 64 | 19 |
| Celecoxib | Celecoxib | 62 | 24 |
| Chlorthalidone | Chlorthalidone | 62 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 62 | 19 |
| Mirtazapine | Mirtazapine | 62 | 18 |
| Alprazolam | Alprazolam | 61 | 15 |
| Azithromycin | Azithromycin | 61 | 59 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 16 |
| Clonidine Hcl | Clonidine Hcl | 56 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 27 |
| Januvia | Sitagliptin Phosphate | 53 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 14 |
| Aripiprazole | Aripiprazole | 50 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 18 |
| Liothyronine Sodium | Liothyronine Sodium | 50 | 15 |
| Rybelsus | Semaglutide | 50 | 19 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 47 | 11 |
| Memantine Hcl | Memantine Hcl | 46 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 45 | 12 |
| Fenofibrate | Fenofibrate,micronized | 45 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 21 |
| Valacyclovir | Valacyclovir Hcl | 44 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 43 | 11 |
| Lamotrigine | Lamotrigine | 43 | 13 |
| Colchicine | Colchicine | 42 | 16 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Klor-Con M20 | Potassium Chloride | 39 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Linzess | Linaclotide | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 19 |
| Estradiol | Estradiol | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 12 |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | 11 |
| Ramipril | Ramipril | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 15 |
| Naproxen | Naproxen | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Lidocaine | Lidocaine | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $820.04 · 44 records | Amgen Inc. | AIRSUPRA, AREXVY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SX-ONE MICROKNIFE, SYNTHROID, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error